161 related articles for article (PubMed ID: 21716815)
1. Valuable lessons from treatment of non-small cell lung cancer with erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Shrimali RK; Correa PD; Rizwanullah M
BMJ Case Rep; 2008; 2008():bcr0620080075. PubMed ID: 21716815
[No Abstract] [Full Text] [Related]
2. Epidermal growth factor receptor inhibitor-related folliculitis.
Tangri N; Al Hammadi A; Gerstein W
Dermatitis; 2007 Sep; 18(3):178-9. PubMed ID: 17725926
[No Abstract] [Full Text] [Related]
3. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
4. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21.
Clark GM; Zborowski DM; Santabarbara P; Ding K; Whitehead M; Seymour L; Shepherd FA;
Clin Lung Cancer; 2006 May; 7(6):389-94. PubMed ID: 16800964
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.
Byrne BJ; Garst J
Curr Oncol Rep; 2005 Jul; 7(4):241-7. PubMed ID: 15946581
[TBL] [Abstract][Full Text] [Related]
6. [Targeted therapies. New hopes, new challenges].
Barlési F
Rev Mal Respir; 2008 Jun; 25(6):661-2. PubMed ID: 18772823
[No Abstract] [Full Text] [Related]
7. [The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].
Wang Y; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2010 Apr; 13(4):375-9. PubMed ID: 20677568
[TBL] [Abstract][Full Text] [Related]
8. Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
Costa DB; Schumer ST; Tenen DG; Kobayashi S
J Clin Oncol; 2008 Mar; 26(7):1182-4; author reply 1184-6. PubMed ID: 18309959
[No Abstract] [Full Text] [Related]
9. Erlotinib-induced rash spares previously irradiated skin.
Lips IM; Koster ME; Houwing RH; Vonk EJ
Strahlenther Onkol; 2011 Aug; 187(8):499-501. PubMed ID: 21789741
[TBL] [Abstract][Full Text] [Related]
10. Acneiform reaction to erlotinib.
Schalock PC; Zug KA
Dermatitis; 2007 Dec; 18(4):230-1. PubMed ID: 18021605
[TBL] [Abstract][Full Text] [Related]
11. Painful annular pustular drug eruption induced by erlotinib in a patient with non-small cell lung cancer.
Lin TC; Wu PY
Cutis; 2011 Dec; 88(6):281-3. PubMed ID: 22372166
[No Abstract] [Full Text] [Related]
12. EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.
Ackerman A; Goldstein MA; Kobayashi S; Costa DB
J Thorac Oncol; 2012 Oct; 7(10):e19-20. PubMed ID: 22982663
[No Abstract] [Full Text] [Related]
13. Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Cho YT; Chen KL; Sheen YS; Yang CW; Liau JY; Cheng YP; Chu CY
JAMA Dermatol; 2017 Sep; 153(9):906-910. PubMed ID: 28538945
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
Welsh JW; Komaki R; Amini A; Munsell MF; Unger W; Allen PK; Chang JY; Wefel JS; McGovern SL; Garland LL; Chen SS; Holt J; Liao Z; Brown P; Sulman E; Heymach JV; Kim ES; Stea B
J Clin Oncol; 2013 Mar; 31(7):895-902. PubMed ID: 23341526
[TBL] [Abstract][Full Text] [Related]
15. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
Cohen MH; Johnson JR; Chattopadhyay S; Tang S; Justice R; Sridhara R; Pazdur R
Oncologist; 2010; 15(12):1344-51. PubMed ID: 21148614
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.
Berge EM; Aisner DL; Doebele RC
J Thorac Oncol; 2013 Sep; 8(9):e83-4. PubMed ID: 23945392
[No Abstract] [Full Text] [Related]
17. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
Watanabe S; Tanaka J; Ota T; Kondo R; Tanaka H; Kagamu H; Ichikawa K; Koshio J; Baba J; Miyabayashi T; Narita I; Yoshizawa H
BMC Cancer; 2011 Jan; 11():1. PubMed ID: 21194487
[TBL] [Abstract][Full Text] [Related]
18. Treatment of non-small-cell lung cancer with erlotinib or gefitinib.
Cataldo VD; Gibbons DL; Pérez-Soler R; Quintás-Cardama A
N Engl J Med; 2011 Mar; 364(10):947-55. PubMed ID: 21388312
[TBL] [Abstract][Full Text] [Related]
19. NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer.
Dillon B; Naidoo B; Knight H; Clark P
Lancet Oncol; 2012 Aug; 13(8):764-5. PubMed ID: 23024988
[No Abstract] [Full Text] [Related]
20. Erlotinib or gefitinib for non-small-cell lung cancer.
Kaye FJ; Jantz MA; Dallas J
N Engl J Med; 2011 Jun; 364(24):2367; author reply 2368. PubMed ID: 21675909
[No Abstract] [Full Text] [Related]
[Next] [New Search]
